(5)中枢神经系统预防:鉴于HIV+ DLBCL患者Ki-67增殖指数明显增高、多合并TP53突变,中枢神经系统侵犯风险高[28]。因此,本共识推荐所有初诊患者均行两药或三药(阿糖胞苷+甲氨蝶呤±地塞米松)鞘内注射预防和(或)静脉输注大剂量甲氨蝶呤治疗。. This evidence concerns the gene MKI67 and diffuse large B-cell lymphoma.